ClinicalTrials.gg
RecruitingNCT07851246Updated Oct 9, 2026

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

A Phase 3 interventional study of mRNA Seasonal Flu vaccine and Comparator 1 in Influenza, Human, sponsored by GlaxoSmithKline. Recruiting at 12 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 9, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Planned enrollment
20th of 165
3,000 · median 324
Started
2026
with 2 others
Phase 3
74 of 187
2 open now
Registered
187th of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 20th largest by planned enrollment of the 165 interventional ones that give a count, is one of 3 that started in 2026, is one of 74 in phase 3, and was the 187th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.

03

Conditions studied

  • Influenza, Human

Browse trials for

Keywords

  • Influenza;
  • Seasonal influenza vaccine;
  • Messenger ribonucleic acid vaccine;
  • mRNA vaccine;
  • Immunogenicity;
  • Reactogenicity;
  • Safety
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, attendance to study contacts, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver.
  • A male or female participant between and including 18 to 64 years of age at the time of study intervention administration
  • Participants of may be enrolled, if the participant:

    • has practiced adequate for at least 30 days prior to study intervention administration, and
    • has a negative urine pregnancy test within 24 hours prior to study intervention administration, and
    • has agreed to continue adequate contraception for at least 8 weeks after study intervention administration.

Exclusion criteria

Exclusion Criteria:

  • History of test confirmed influenza infection within 180 days prior to study intervention administration.
  • Confirmed or suspected or immunodeficient condition, except for stable infection meeting protocol-defined stability criteria.
  • History of myocarditis or pericarditis considered causally associated with the administration of an mRNA vaccine.
  • History of or allergic reaction to any previous influenza vaccine.
  • History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
  • History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
  • Acute or unstable chronic conditions as determined by medical history and clinical examination.
  • Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration prior to Visit 2 during the study.
  • Planned administration/administration of prohibited vaccines within protocol-defined time windows before or after study intervention administration.
  • Use of any or non-registered product (other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or their planned use during the study period.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study.
  • Pregnant or lactating female participant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    mRNA Seasonal Flu Vaccine - Cohort 1

    Participants 18 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.

    Biological: mRNA Seasonal Flu vaccine

  • Active comparator
    Comparator 1_Cohort 1

    Participants 18 to 64 years of age will receive a single dose of comparator 1 on Day 1.

    Biological: Comparator 1

  • Experimental
    mRNA Seasonal Flu Vaccine - Cohort 2

    Participants 60 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.

    Biological: mRNA Seasonal Flu vaccine

  • Active comparator
    Comparator 2_Cohort 2

    Participants 60 to 64 years of age will receive a single dose of comparator 2 on Day 1.

    Biological: Comparator 2

Interventions

  • BiologicalmRNA Seasonal Flu vaccine

    One dose of the mRNA Flu vaccine received intramuscularly.

  • BiologicalComparator 1

    One dose of the comparator vaccine received intramuscularly.

  • BiologicalComparator 2

    One dose of the comparator vaccine received intramuscularly.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Antigen 1 Titer

    Time frame: At Day 29

  2. GMT of Antigen 2 Titer

    Time frame: At Day 29

  3. Percentage of participants with Antigen 1 seroconversion rate (SCR)

    Time frame: From Day 1 to Day 29

  4. Number of participants with solicited administration site adverse events

    Time frame: Day 1 to Day 7

  5. Number of participants with systemic adverse events

    Time frame: Day 1 to Day 7

  6. Number of participants with unsolicited adverse events

    Time frame: Day 1 to Day 28

  7. Number of participants with serious adverse events (SAEs)

    Time frame: Day 1 to Day 181

  8. Number of participants with adverse events of special interest (AESIs)

    Time frame: Day 1 to Day 181

  9. Number of Participants with any Laboratory abnormalities

    Time frame: At Day 1 (pre-dose) and at Day 29 (post - dose)

Secondary outcomes

  1. GMT of Antigen 1 and Antigen 2 antibodies

    Time frame: At Day 29

  2. Percentage of Participants with Antigen 1 and Antigen 2 antibodies SCR

    Time frame: Day 1 to Day 29

  3. Geometric Mean Increase (GMI) of Antigen 1 Titer

    Time frame: At Day 29 relative to baseline (Day 1)

  4. GMI of Antigen 2 Titer

    Time frame: At Day 29 relative to baseline (Day 1)

  5. Percentage of Participants with Antigen 1 Seroprotection Rate (SPR)

    Time frame: At Day 1 and Day 29

  6. Percentage of Participants with Antigen 2 SCR

    Time frame: Day 1 to Day 29

  7. GMT of virus neutralization titers

    Time frame: At Day 29

  8. Percentage of participants with seroconversion of virus neutralization titers

    Time frame: Day 1 to Day 29

  9. GMI of virus neutralization titers

    Time frame: At Day 29 relative to baseline (Day 1)

07

Study locations

12 of 12 sites recruiting
  • GSK Investigational Site
    Glendale, Arizona 85308, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85711, United States
    Recruiting
  • GSK Investigational Site
    San Diego, California 92123, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33186, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Meridian, Idaho 83642-3154, United States
    Recruiting
  • GSK Investigational Site
    Valparaiso, Indiana 46383, United States
    Recruiting
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
    Recruiting
  • GSK Investigational Site
    Hartsdale, New York 10530, United States
    Recruiting
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
    Recruiting
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
    Recruiting
  • GSK Investigational Site
    Fort Worth, Texas 76135, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 9 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Jul 9, 2027
CompletionEst.
Jul 9, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
12 sites added — first site in United States
Show 12 added (12 United States)
  • GSK Investigational Site · Glendale, United States
  • GSK Investigational Site · Tucson, United States
  • GSK Investigational Site · San Diego, United States
  • GSK Investigational Site · Miami, United States
  • GSK Investigational Site · Miami Lakes, United States
  • GSK Investigational Site · Meridian, United States
  • GSK Investigational Site · Valparaiso, United States
  • GSK Investigational Site · Lenexa, United States
  • GSK Investigational Site · Hartsdale, United States
  • GSK Investigational Site · Spartanburg, United States
  • GSK Investigational Site · DeSoto, United States
  • GSK Investigational Site · Fort Worth, United States
Oct 9, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    12 sites added — first site in United States
    Show 12 added (12 United States)
    • GSK Investigational Site · Glendale, United States
    • GSK Investigational Site · Tucson, United States
    • GSK Investigational Site · San Diego, United States
    • GSK Investigational Site · Miami, United States
    • GSK Investigational Site · Miami Lakes, United States
    • GSK Investigational Site · Meridian, United States
    • GSK Investigational Site · Valparaiso, United States
    • GSK Investigational Site · Lenexa, United States
    • GSK Investigational Site · Hartsdale, United States
    • GSK Investigational Site · Spartanburg, United States
    • GSK Investigational Site · DeSoto, United States
    • GSK Investigational Site · Fort Worth, United States
    + 2 other changes: verification date and date precision
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851246
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 1, 2026
Primary completion
Jul 9, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion